Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.

Francesc Formiga, Julio Nuñez, María José Castillo Moraga, Marta Cobo Marcos, María Isabel Egocheaga, Concha F García-Prieto, Angel Trueba-Sáiz, Arantxa Matalí Gilarranz, José María Fernández Rodriguez

Journal: Heart failure reviews 2024;29(1):179-189

PMID: 37861854

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a common condition in clinical practice, affecting more than half of patients with HF. HFpEF is associated with morbidity and mortality and with considerable healthcare resource utilization and costs. Therefore, early diagnosis is crucial to facilitate prompt management, particularly initiation of sodium-glucose co-transporter 2 inhibitors. Although European guidelines define HFpEF as the presence of symptoms with or without signs of HF, left ventricular EF ≥ 50%, and objective evidence of cardiac structural and/or functional abnormalities, together with elevated natriuretic peptide levels, the diagnosis of HFpEF remains challenging. First, there is no clear consensus on how HFpEF should be defined. Furthermore, diagnostic tools, such as natriuretic peptide levels and resting echocardiogram findings, are significantly limited in the diagnosis of HFpEF. As a result, some patients are overdiagnosed (i.e., elderly people with comorbidities that mimic HF), although in other cases, HFpEF is overlooked. In this manuscript, we perform a systematic narrative review of the diagnostic approach to patients with HFpEF. We also propose a comprehensible algorithm that can be easily applied in daily clinical practice and could prove useful for confirming or ruling out a diagnosis of HFpEF.

© 2023. The Author(s).

Address: Servicio de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain. [email protected].; Servicio de Cardiología, Hospital Clínico Universitario de Valencia-España, Valencia, Spain.; Departamento de Medicina, Universidad de Valencia, Fundación de Investigación INCLIVA, Valencia, Spain.; Medicina Familiar y Comunitaria, Centro de Salud Barrio Bajo, Sanlúcar de Barrameda, Cádiz, Spain.; Servicio de Cardiología, Hospital Universitario Puerta de Hierro Majadahonda (IDIPHISA), Madrid, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.; Medicina Familiar y Comunitaria, Centro de Salud Isla de Oza, Madrid, Spain.; Medical Affairs Department, Eli Lilly and Company España, Alcobendas, Madrid, Spain.; Medical Affairs Department, Boehringer Ingelheim, Sant Cugat del Vallés, Barcelona, Spain.; Área Cardiorrenometabólica del Servicio de Medicina Interna del Hospital Universitario Ramon y Cajal, Madrid, Spain.; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.